Products for Research Use Only
RegisterLogin

Mitiperstat

CAT: 0804-HY-145581-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-145581-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mitiperstat (AZD4831) is an effective oral inhibitor of myeloperoxidase (MPO) . Mitiperstat inhibits MPO and thyroid peroxidase (TPO) with IC50s of 1.5 nM and 0.69 μM. Mitiperstat exhibits a weak inhibitory activity against CYP3A4 with an IC50 of 6 μM. Mitiperstat can reduce inflammation and improve microvascular function, and it can be used in studies related to heart failure, preserved or mildly reduced ejection fraction, non-alcoholic fatty liver disease, and chronic obstructive pulmonary disease[1][2][3][4].
CAS Number
1933460-19-5
Product Name Alternative
AZD4831
UNSPSC
12352005
Hazard Statement
H302, H314
Target
Cytochrome P450; Glutathione Peroxidase
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/mitiperstat.html
Purity
99.12
Solubility
1 M HCl : 50 mg/mL (adjust pH to 1 with 1 M HCl) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=S)C(NC=C2)=C2N1CC3=C(C=C(C=C3)Cl)[C@H](N)C
Molecular Formula
C15H15ClN4OS
Molecular Weight
334.82
Precautions
H302, H314
References & Citations
[1]Joanna Parkinson, et al. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacol Res Perspect. 2024 Apr;12 (2) :e1184.|[2]Lars H Lund, et al. Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. Eur J Heart Fail. 2023 Sep;25 (9) :1696-1707.|[3]Carolyn S P Lam, et al. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results. J Card Fail. 2024 Jan;30 (1) :104-110.|[4]Inghardt T, et al., Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction. J Med Chem. 2022 Sep 8;65 (17) :11485-11496.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
BA3445-25Mitiperstat

Popular Products